A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Clinical trial NCT06164951 · COMPLETED
Trial details
- NCT number
- NCT06164951
- Sponsor
- QED Therapeutics, a BridgeBio company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-10
- Primary completion
- 2025-12-18
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.